Welcome to YLOAN.COM
yloan.com » College-University » New targeted therapy reduced 80% of tumours in B-Raf study
College-University Vocational-Trade-Schools Root Category Home-Schooling scholarships books certification students

New targeted therapy reduced 80% of tumours in B-Raf study

New targeted therapy reduced 80% of tumours in B-Raf study


Antibody suppliers to cancer research groups commonly list BRAF on their antibody database. A gene which encodes the B-Raf cell-signalling protein, it plays an important role in cell division, growth and secretion. However, BRAF can also function as an oncogene, being expressed in 60% of malignant melanomas. A recent study using B-Raf antibodies revealed a new targeted therapy that shrank advanced melanoma tumours in 80% of the patient group.

A member of the raf/mil group of serine threonine protein kinases, B-Raf is expressed mainly in the brain and central nervous system. It is known to play a role in the MAP kinase/ERKs cell signalling pathway, regulating mitosis by controlling mitogenic signalling from the membrane to the nucleus. In response to NGF (nerve growth factor) triggering, B-Raf activates MAP kinase, an essential protein in mitosis.

Although this mechanism is tightly controlled, B-Raf is easily mutated. Hereditary mutations cause birth defects, while acquired mutations lead to oncogenic changes. Over 30 BRAF oncogene variants have been identified, although over 90% of human BRAF cancers are caused by just one - V600E. Mutated BRAF varies in its expression, accounting for 1 3 % of lung cancers but up to 60% of malignant melanomas. It is also widespread in colorectal and papillary thyroid cancer. With metastatic melanomas on the increase, and no significant advances in treatment since the 1990s, it is plain a drug that inhibits BRAF oncogenic activity is needed.


This may have happened. Recently, a team from the Memorial Sloan-Kettering Cancer Centre developed a new drug specifically targeting BRAF at the cellular level. In human volunteers suffering from advanced melanomas, treatment with the drug (codenamed PLX 4032), resulted in shrinkage of 80% of tumours. The trial has now progressed to Phase 3.

We at Novus Biologicals have almost 18,700 products on our antibody database devoted to cancer. Many of them, like our B-Raf antibodies, are at the forefront of medical research.
BE-DO-HAVE - The Most Important Process You Will Learn - Part II of III 642-902 study materials 9L0-062 braindump College Essays - How To Make A Good One Better For College Admissions Distance Learning in India- A Boon for Numerous Aspiring Students How to get scholarships from colleges Study About Birthday Party Ideas For Your Kid's Upcoming Birthday Celebration Posing Secrets by Malcolm Boone - Learn The Proper Poses For Your Models! Easy Scholarships For College - Scholarships Can Help You Pay For Studying NS0-153 study guide SY0-201 braindump 642-832 exam dump Best NCAA Football Apparels for College Students
print
www.yloan.com guest:  register | login | search IP(216.73.216.35) California / Anaheim Processed in 0.016780 second(s), 7 queries , Gzip enabled , discuz 5.5 through PHP 8.3.9 , debug code: 10 , 2135, 249,
New targeted therapy reduced 80% of tumours in B-Raf study Anaheim